Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Withdrawn 1Completed 1Approved for marketing 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 2NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Carcinoma, Medullary 3Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms, Nerve Tissue 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasms 2Lung Neoplasms 2Lung Diseases 2Head and Neck Neoplasms 2Carcinoma, Bronchogenic 2Carcinoma 2Adenocarcinoma 2Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Solid Tumors 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neoplasms, Glandular and Epithelial 1Multiple Endocrine Neoplasia Type 2a 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1

Interventions

vandetanib 10selpercatinib 5cabozantinib 4pralsetinib 3yeast-CEA vaccine 1rovalpituzumab tesirine 1motesanib diphosphate 1anlotinib 1Sorafenib 1Ranitidine 1Omeprazole 1Melphalan 1Dexamethasone 1Calcium Aluminosilicate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Medullary × pralsetinib × Clear all
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 3 FDA
EndocrineGastrointestinalHead & NeckNETThoracic

Thyroid Cancer, Papillary, Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Medullary, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 2a

NCT04760288 2024-01-05

AcceleRET-MTC

Hoffmann-La Roche

Phase 3 Withdrawn

Carcinoma, Medullary

NCT04204928 2021-08-13

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Blueprint Medicines Corporation

Approved for marketing
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡